tumours in the region of the third ventricle. Headache is not strictly an ocular symptom, but it comes within the ophthalmologist's purview. In this series it was absent in 53 patients. It is worth noting that in only 2 of those cases in which it did occur did the nature of the headache suggest an ocular origin.
The Treatment of Pituitary Tumours by Joe Pennybacker FRCS (Oxford)
The ophthalmologist's concern with pituitary tumours is largely confined to the two types which cause visual symptoms, namely the chromophobe and chromophil adenomata. Both types, by erupting upwards from the sella, can compress the optic nerves and chiasma and cause the characteristic field defects and loss of acuity which have been described. Visual symptoms are the surgeon's chief concern too, because failure of vision is the common indication for surgical treatment of these tumours.
We speak of chromophobe and chromophil adenomata because generally the predominant cell type of the the tumour produces a characteristic clinical picture. The chromophil tumours cause acromegaly in greater or less degree and the chromophobe tumours produce varying degrees of hypopituitarism; loss of body hair, amenorrhma, impotence, lack of energy, &c. But this is not always so: sometimes a chromophobe tumour will cause enlargement of the sella and a chiasmal lesion with no symptoms or signs of hypopituitarism. And sometimes there is a mixture of the features of acromegaly and hypopituitarism, and in these the tumour is best described as a mixed cell adenoma.
Most pituitary tumours grow very slowly. It is common knowledge, for instance, how easily acromegaly can slip up on one, unnoticed by the patient or those who see him every day. I saw a doctor recently whom I had not seen for about twenty years. I remembered him as a rather heavyfeatured young man, but he is now a well-marked acromegalic. He has no symptoms and the change in his appearance has been so gradual that his family and his partner had not noticed it. I have no doubt that he has had a cbromophil tumour for at least twenty years, and even after that time it has done nothing more than produce a very gradual alteration in his appearance. Similarly, it is very common to see a middle-aged person with a chromophobe adenoma who on enquiry will be found to have symptoms of hypopituitarism dating back to adolescence or early adult life. In some cases, the length of the history is such that we may be misled into thinking that we are dealing with a congenital tumour such as a craniopharyngioma. Or indeed we might wonder whether pituitary adenomata are themselves congenital tumours.
Not all pituitary tumours grow so slowly of course. There are some which grow very rapidly and recur quickly after operation. Some of these are carcinomata, and they have distinctive histological features. Some adenomata develop cysts, and others are prone to heemorrhage, both processes leading to a rapid expansion of the tumour.
Another feature which interests me is the difference in the growth pattern of chromophobe and chromophil adenomata in relation to the sella turcica, and the optic nerves and chiasma. The chromophobe tumours expand the sella and project upwards to compress the optic nerves and chiasma very readily, but the chromophobe tumours may produce gross enlargement of the sella without any visual disturbance at all. The fact of the chromophil tumour being confined within the sella is, I think, responsible for a common symptom in acromegaly, namely severe bitemporal headache. This can be very distressing at times, and one acromegalic (R.I. 7976/43) was admitted as an emergency because of it. It had come on two or three days after a dental extraction, and he was obviously in very severe pain when he came into hospital. He described it as a hammering between the temples, and there was a good deal of vomiting. There was no field defect or loss of acuity, the fundi were normal, as was the spinal fluid pressure, and so we assumed that the headache was not due to increased intracranial pressure. This kind of bitemporal headache in acromegaly usually responds dramatically to X-ray treatment, but while we were arranging for this, the headache suddenly ceased. I saw him about an hour later and found a well man, obviously relieved, but he noticed that something had happened to his vision and he now had a defect in both temporal fields. It would seem likely that the tumour had ruptured through the dia-phragma sella and thus 'decompressed' itself. This patient has been kept under regular observation and he has remained well during the past eighteen years. He leads an active life as a farmer, the bitemporal defect has not progressed and the visual acuity is normal.
This case demonstrates another feature of acromegaly which is worth noting. When a chromophobe tumour produces visual symptoms, these are usually progressive and will go on to blindness unless they are relieved. Many acromegalics, however, have no visual symptoms, and those who do develop field defects may remain stationary for many years, and it is uncommon for them to progress to serious impairment of vision. This accounts for the fact that out of 171 cases of pituitary tumour verified at operation in Oxford, there have only been 6 cases of acromegaly, whereas there were 65 cases of acromegaly which did not require operation.
The operation for pituitary tumours is an incomplete one, directed primarily to relieving pressure on the optic nerves and chiasma. The tumour is usually approached by the sub-frontal route, the capsule is incised and the interior sucked out, curetted or removed with rongeurs. This intracapsular removal reduces the bulk of the tumour and the upper part of the capsule can then be pulled down from above to free the chiasma, and from both sides to free the optic nerves. But there is tumour left and it will recur in time like any other tumour which is not completely removed. It is because of this that radiation treatment of the remnant has been a common practice for many years, and there is no longer any doubt about its value. Indeed many regard these tumours as so highly radiosensitive that they should be given this kind of treatment before surgery is considered. At the Lahey Clinic in Boston, I believe only about 12% of pituitary tumours find their way to the operating room: the others are all treated by radiation. Being somewhat conservative in the use of the knife and the shedding of blood, I must say that this approach appeals to me: if one can spare a person a major operation on his head and do as much for him with another method of treatment which carries no risk, this is obviously all to the good.
When the surgeon sees a patient with a pituitary tumour, the first decision is usually as to whether or not his symptoms demand treatment, and if so, whether operation or radiation treatment should be advised. There is no doubt that we see these patients earlier than we used to do, I suppose because the country is being populated by bright young doctors who make the diagnosis at a stage when it really depends on an X-ray of the sella. Although the majority of cases still come from the ophthalmologists, there are many from the physicians and gyneecologists who have patients sent to them suffering from anwmia, lack ofenergy, amenorrhoea, &c. They all have a large sella, most have some field defect of which they might not be aware, and a few have no visual defect at all. Not long ago, I saw 3 patients with pituitary adenomata at a single outpatient clinic. One had come from a physician, 1 from a gynecologist and 1 from a general practitioner. Each had only an upper temporal defect in one field, and all had normal acuity. For these I would recommend radiation treatment with the provision that a close watch can be kept on the fields and acuity during the treatment. We see these patients at weekly intervals, and they are told to report at once if they notice any significant change in their vision during the intervals. This is because radiation is thought sometimes to cause a temporary swelling of the tumour, and if a nerve is already much compressed, further swelling might cause irreparable damage, but I have not known this to happen in any of the cases which we have had under observation.
The clinical effects of radiation treatment are usually quite definite. March 1958: A woman aged 57 (R.I. 183130), with a considerable hypertension (200/120) and an enlarged sella, she was one of the group who had been devoid of body hair throughout her life, despite which she had borne 4 children. There was a complete hemianopia in the left eye, and a small notch in the upper temporal field on the right side, V.A. was 6/36, J.16 left, and 6/12, J.6 right. Knowing that she had high blood pressure, she was anxious to avoid operation, so she was given a course of radiation treatment. By October 1958 the acuity was 6/18, J.6 left, and 6/9, J.2 right. There was still an upper quadrant defect in each field, but by February 1961 the fields were full to a 5 mm white object. There was still a relative upper quadrant defect to red objects in the left eye.
The gross effects of radiation treatment, i.e. in reducing the bulk of the tumour, can be seen by air-encephalography. Indeed, these effects may sometimes be more than we have bargained for, as within the past six months we have had 2 patients with large pituitary tumours treated by operation and radiation who have done well as regards vision, but have developed cerebrospinal rhinorrhcea. Both have had attacks of meningitis. One we have explored and found no evidence of tumour at all. The other is in hospital at present recovering from meningitis, but an airencephalogram shows that the tumour has shrivelled up. Presumably in both cases, the tumour has eroded the sphenoid or posterior ethmoid air cells, and as it shrivelled after radiation treatment, its plugging effect ceased. Such fistule have to be closed, and this can be a difficult technical problem.
There are at least two groups of tumours which do not respond satisfactorily to radiation and these are the cystic ones and those in which a hemorrhage has occurred. It may be impossible to identify these changes on clinical grounds, but if there is a story of a rapid or sudden loss of vision, with headache, vomiting, and pain behind the eyes, such cases usually demand operation, and promptly. The following is a case in point. F S, female aged 60 (R.I. 278112/59); admitted 20.8.59-She had had mild symptoms of hypopituitarism for about two years and for six months had thought that her sight was failing. Ten days before admission, on returning from watching a tennis match, she developed a severe headache which she described as being behind the eyes. This persisted and she vomited frequently, and her sight became misty. She was admitted to another hospital where it was found that she had a bitemporal hemianopia and an enlarged sella. The spinal fluid was clear and colourless and the pressure was normal. When she was transferred to the Radcliffe Infirmary, the headache had largely abated, leaving her with a feeling of pressure behind the eyes. The bitemporal defect was confirmed, and V.A. was 6/36, J. 16 in each eye. At operation, there was a tense bluish tumour projecting upwards from the sella. Nothing could be obtained on aspiration with a needle, but when the capsule was incised, dark tarry blood escaped and about 8 ml of this was collected. The interior of the tumour was curetted, and the accessible portion of the capsule excised. She improved rapidly and had a course of radiation treatment after operation, and twelve months later she regarded her general health and eyesight as normal. The acuity was 6/9, J.1 in each eye, but although the peripheral fields were full, there was still a bitemporal defect to small objects on the Bjerrum's screen.
The result of treatment, whether surgery or radiotherapy or a combination of both, depends to a large extent on how long the visual pathway has been subjected to pressure. The most dramatic response occurs in those cases of rapid loss of vision in which an operation such as I have described may bring about a full recovery of the fields and acuity, often within a few days. On the other hand, if there is bilateral optic atrophy and a long-standing field defect, operation may do little more than prevent further loss, but even this may be very valuable in preventing complete blindness.
There have been two or three important advances in the management of these tumours. Hormone therapy has undoubtedly given the surgeon a good deal more leeway: in the old days we were always afraid to remove too much of the tumour, because some of these patients made good visual recoveries but were left as pituitary wrecks. There is no doubt that hormones have made the operation and the post-operative period less harrowing, and they are highly effective in the treatment of the general symptoms of hypopituitarism. Of only slightly less value to the sur-geon is the introduction ofintravenous urea for the reduction of intracranial pressure. This substance shrinks the brain to such an extent that exposure of these tumours is usually quite easy. A third minor technical advance is the small craniotomy: a small bone flap gives all the room that one can use, and there is less risk of complications such as hlematomata. As I see it now, the surgery of pituitary tumours is safer than it has ever been, and in radiation therapy we have another method, the safety and relative value of which we have yet to establish. And as operation may be called for at any time, I think it important that the neurosurgeon be asked to see these patients as soon as the diagnosis is made.
The Endocrinology of Pituitary Tumours by E J Ross MD MRCP (London)
Tumours in the region of the pituitary are of interest to ophthalmologists because of their local effects to the fibres of the optic chiasma. Their endocrine interest and importance lies in the local damage caused by their presence to the various parts of the pituitary gland and its functionally related areas in the hypothalamus. In its capacity as the master gland, failure of pituitary function secondarily affects the secretion of other endocrine glands of the body, in particular, the gonads, adrenal cortex and thyroid.
The local effect of an expanding tumour within the sella turcica is failure of production of trophic hormones. The clinical effects of failure of these pituitary hormones is typically manifested in a characteristic sequence. It has been shown experimentally (Ganong & Hume 1956) that when varying amounts of pituitary tissue were removed from dogs, gonadal function was the first to be depressed, then thyroid, and finally adrenocortical depression was seen. This sequence of selective failure ofend-organs is seen in many cases clinically (Hubble 1952 , Nurnberger & Korey 1953 ; in others signs and symptoms of adrenal insufficiency are noted before those of hypothyroidism (Mogensen 1957). In all cases, however, the cells or perhaps the enzymes which are most sensitive to destruction by pressure are those responsible for the production of gonadotrophins. The result is the cessation of menstruation or impotence, decreased growth of beard and loss of pubic and axillary hair which may precede other symptoms and signs of the presence of a pituitary tumour by many years. The loss of body hair is in part also due to loss of adrenal androgens. Scalp hair retains its previous rate of growth.
Either thyroid or adrenal hypofunction may be the next to appear. Clinically symptoms of
